---
title: "FDA Revises Nonclinical Testing Rules to Advance Alternatives to Animal Studies"
id: "fda-news-releases-0-fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing"
canonical_url: "https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "FDA News Releases"
source_url: "http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing"
published_at: "2026-09-21T12:58:34.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA Revises Nonclinical Testing Rules to Advance Alternatives to Animal Studies
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** FDA News Releases
- **Source URL:** [Original Journal Publication](http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing)
- **Published At:** 2026-09-21T12:58:34.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- The FDA issued a direct final rule on September 21, 2026, updating regulatory language to clarify that **non-animal methods** may be used where appropriate to generate safety information for human drugs and biologics before studies in humans. - The rule replaces terms such as “animal tests,” “animal studies,” “preclinical,” and “in vitro” with **“nonclinical tests”** and **“nonclinical studies”**, and defines these terms in line with the Food and Drug Omnibus Reform Act of 2022 (FDORA). - The update recognizes newer testing approaches — including methods using human cells, organs-on-chips, computer models and other advanced technologies — as possible ways to provide evidence needed to begin human studies, without eliminating or prohibiting animal studies. - The rule does not change evidentiary standards, impose new costs or requirements on drug developers, or suggest animal testing is the only acceptable approach for regulatory decisions. - The FDA launched an initial database of New Approach Methodologies (**NAMs**) use cases, featuring 25 examples drawn from publicly available FDA review materials to demonstrate practical applications. - The actions support the agency’s Innovation and Global Leadership pillar and align with HHS initiatives such as Operation TrialBlazer to modernize clinical research and accelerate therapeutic development. - The FDA invites public comment; the direct final rule was published alongside a companion proposed rule and Federal Register notices. If significant adverse comments are received, the agency will withdraw the direct final rule and proceed using the standard notice-and-comment process. - The announcement reiterates the agency’s aim to give sponsors flexibility to use the testing approach that best answers their scientific question while maintaining rigorous standards to protect patients. - Contact and resource links include Federal Register notices for the direct final and proposed rules, FDA procedures for direct final rules, the NAMs database, and a progress report titled “Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward.”
## Clinical Analysis & Structured Key Points
FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home News & Events FDA Newsroom Press Announcements FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing Press Announcements In this section More Press Announcements For Immediate Release: September 21, 2026 The U.S. Food and Drug Administration today issued a direct final rule that updates its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use before they’re tried in humans. The update reflects advances in science and technology that have expanded the range of testing options available in human drug development, including methods using human cells, organs-on-chips, computer models and other advanced technologies. “This new rule supports the Trump Administration’s push to explore ways to complement, or where appropriate, replace animal studies with methods that may better predict how medicines will actually affect people,” said Acting FDA Commissioner of Food and Drugs, Kyle Diamantas, J.D. “It gives scientists and drug developers greater flexibility to use the testing approach that best addresses their scientific question. Our goal is not to replace one rigid approach with another. It is to support rigorous, modern science — including animal studies when they remain appropriate and validated alternatives when they can provide the evidence needed to protect patients.” The rule replaces terms like “animal tests” and “animal studies” with the terms “nonclinical tests” and “nonclinical studies.” Related terms, including “preclinical” and “in vitro,” are also replaced. The rule defines “nonclinical test” and “nonclinical study” in line with the Food and Drug Omnibus Reform Act of 2022 (FDORA). The law recognizes newer methods that do not use animals and traditional animal studies as possible ways to provide the evidence needed to begin studies in people. The rule removes language that could suggest that animal testing is the only acceptable way to generate safety information for regulatory decisions in products intended for human use. It does not eliminate or prohibit animal studies, change evidentiary standards or impose new costs or requirements on drug developers. To demonstrate their practical application, the FDA also launched a database featuring specific uses of New Approach Methodologies (NAMs) . The initial release includes 25 examples drawn from publicly available FDA review materials. The new rule and database are among several actions that the Department of Health and Human Services, including the FDA, is taking to advance drug development using NAMs, which are innovative testing methods that may better reflect human biology. Developers may use NAMs to generate safety information when the methods are adequately validated and appropriate for the product and regulatory question. These actions are in line with Pillar 1 — Innovation and Global Leadership — of the FDA’s Public Health Pillars . By formally recognizing a broader range of scientific approaches, the FDA is keeping pace with emerging technologies and strengthening the agency’s leadership in regulatory science. Encouraging the use of NAMs also complements Operation TrialBlazer , the Department of Health and Human Services initiative to modernize clinical research and accelerate the development of life-saving treatments. Clearer terminology and regulatory expectations can reduce avoidable uncertainty as sponsors develop nonclinical evidence and prepare applications to begin clinical trials. The agency is inviting the public, including clinicians, parents, caregivers, the scientific community, industry, and others, to comment on the rule. For additional information, see the Federal Register notices announcing the direct final rule, the companion proposed rule , and the comment period. If the FDA receives significant adverse comments on the direct final rule, the agency will withdraw it and continue rulemaking through the standard notice-and-comment process using the companion proposed rule. Publishing both simultaneously ensures the rulemaking can proceed efficiently under either scenario. Additional Information Nonclinical Testing Terminology Direct Final Rule Nonclinical Testing Terminology Proposed Rule FDA Direct Final Rule Procedures Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward Media: FDA Request for Comment 202-690-6343 Consumer: 888-INFO-FDA The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. ### Content current as of: 09/21/2026 Regulated Product(s) Biologics Drugs Topic(s) New Approach Methodologies Follow FDA Follow @US_FDA on X Follow FDA on Facebook Follow @FDAMedia on X Feedback Back to Top
## Related Clinical Research

- [Nurses' Role in Comprehensive Endometriosis Care: Beyond Pain Management](https://medichelpline.com/clinical-feed/pubmed-42765750.md) (DOI: 10.1097/NSG.0000000000000463)
- [FDA Removes Boxed Warning for Menopausal Hormone Therapy: Key Points for Nurses](https://medichelpline.com/clinical-feed/pubmed-42765755.md) (DOI: 10.1097/NSG.0000000000000411)
- [Novo Nordisk outlines obesity and direct-to-consumer push, pledges five 'multi-blockbusters' by 20](https://medichelpline.com/clinical-feed/stat-news-1-stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to-consumer-work.md)
- [Trump Announces GENEROUS Medicaid Drug-Discount Model; 40 States Reportedly Signed So Far](https://medichelpline.com/clinical-feed/stat-news-0-stat-trump-touts-pharma-deals-to-offer-cheaper-drugs-to-state-medicaid-programs.md)
- [Correction Notice: Physician Management of Immunoglobulin in Canada — S1 File Update](https://medichelpline.com/clinical-feed/plos-one-0-correction-physician-management-of-immunoglobulin-in-canada-a-qualitative-study.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.